Literature DB >> 27496194

Murine Flt3 ligand-generated plasmacytoid and conventional dendritic cells display functional differentiation in activation, inflammation, and antigen presentation during BCG infection in vitro.

Chuang Meng1, Xiaoyan Wang1, Zhengzhong Xu1, Maozhi Hu1,2, Jiaying Liu1, Zhiming Pan1, Xiang Chen3, Xinan Jiao4.   

Abstract

Dendritic cells (DCs) are composed of distinct subsets. Their immunologic functions (especially in pathogenic infection, such as with mycobacteria) are poorly understood, largely because of their rarity and difficulty of preparation. We used the murine Fms-like tyrosine kinase 3 (Flt3) ligand to generate conventional DCs (FL-cDCs) and plasmacytoid DCs (FL-pDCs) and further evaluated their immunological responses to bacillus Calmette-Guérin (BCG) infection in vitro. BCG cells were observed inside both FL-cDCs and FL-pDCs by confocal microscopy, as confirmed by flow cytometric analysis showing a low infection rate of approximately 6 %, which was similar to in vivo results. The CD40, CD80, CD86, and MHC-II proteins were significantly upregulated in both FL-cDCs and -pDCs beginning at 4 h post-BCG exposure. FL-pDCs secreted TNF-α and IL-6 earlier and at significantly higher levels in the first 12 h following infection, but demonstrated delayed and weak activation and maturation compared to FL-cDCs. Although both subsets proved capable of presenting a mycobacterial antigen, FL-pDCs exhibited weaker activity in this respect than did FL-cDCs. In summary, the existence of FL-generated cDCs and pDCs imply functional differentiation in activation, inflammation, and antigen presentation, although both cells types participated extensively in the immune response to BCG infection.

Entities:  

Keywords:  BCG; Dendritic cells; Flt3 ligand; Immune response; In vitro; Subset

Mesh:

Substances:

Year:  2016        PMID: 27496194     DOI: 10.1007/s11626-016-0076-3

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  33 in total

1.  Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo.

Authors:  Andrea J Wolf; Beth Linas; Giraldina J Trevejo-Nuñez; Eleanor Kincaid; Toshiki Tamura; Kiyoshi Takatsu; Joel D Ernst
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

2.  CD8+, CD8-, and plasmacytoid dendritic cell generation in vitro using flt3 ligand.

Authors:  Shalin H Naik; Meredith O'Keeffe; Anna Proietto; Hubertus Hochrein Ken Shortman; Li Wu
Journal:  Methods Mol Biol       Date:  2010

3.  Enhanced antigen-presenting activity and tumour necrosis factor-alpha-independent activation of dendritic cells following treatment with Mycobacterium bovis bacillus Calmette-Guérin.

Authors:  K D Kim; H G Lee; J K Kim; S N Park; I S Choe; Y K Choe; S J Kim; E Lee; J S Lim
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

4.  Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation.

Authors:  R M Steinman
Journal:  Mt Sinai J Med       Date:  2001-05

5.  Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures.

Authors:  Shalin H Naik; Anna I Proietto; Nicholas S Wilson; Aleksandar Dakic; Petra Schnorrer; Martina Fuchsberger; Mireille H Lahoud; Meredith O'Keeffe; Qi-xiang Shao; Wei-feng Chen; José A Villadangos; Ken Shortman; Li Wu
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

6.  Mycobacterium tuberculosis inhibits maturation of human monocyte-derived dendritic cells in vitro.

Authors:  Willem A Hanekom; Megan Mendillo; Claudia Manca; Patrick A J Haslett; M Ruby Siddiqui; Clifton Barry; Gilla Kaplan
Journal:  J Infect Dis       Date:  2003-07-09       Impact factor: 5.226

7.  Mycobacterium bovis bacillus Calmette-Guérin-infected dendritic cells potently activate autologous T cells via a B7 and interleukin-12-dependent mechanism.

Authors:  Eleanor J Cheadle; Peter J Selby; Andrew M Jackson
Journal:  Immunology       Date:  2003-01       Impact factor: 7.397

8.  Antigen crosspresentation by human plasmacytoid dendritic cells.

Authors:  Guillaume Hoeffel; Anne-Claire Ripoche; Diana Matheoud; Michelina Nascimbeni; Nicolas Escriou; Pierre Lebon; Farhad Heshmati; Jean-Gérard Guillet; Monique Gannagé; Sophie Caillat-Zucman; Nicoletta Casartelli; Olivier Schwartz; Henri De la Salle; Daniel Hanau; Anne Hosmalin; Concepción Marañón
Journal:  Immunity       Date:  2007-09       Impact factor: 31.745

9.  Plasmacytoid dendritic cells infiltrate the skin in positive tuberculin skin test indurations.

Authors:  Emily Bond; Frank Liang; Kerrie J Sandgren; Anna Smed-Sörensen; Peter Bergman; Susanna Brighenti; William C Adams; Senait A Betemariam; Molebogeng X Rangaka; Christoph Lange; Robert J Wilkinson; Jan Andersson; Karin Loré
Journal:  J Invest Dermatol       Date:  2011-08-18       Impact factor: 8.551

10.  Dendritic Cells Activate and Mature after Infection with Mycobacterium tuberculosis.

Authors:  Adane Mihret; Gezahagne Mamo; Mesfin Tafesse; Asrat Hailu; Shreemanta Parida
Journal:  BMC Res Notes       Date:  2011-07-21
View more
  3 in total

1.  I-alowCD11bhigh DC Regulates the Immune Response in the Eyes of Experimental Autoimmune Uveitis.

Authors:  Yu Zhao; Jingwen Wang; Zhang Min; Li Peng; Shuhong Qi; Wei Lin
Journal:  Mediators Inflamm       Date:  2020-03-10       Impact factor: 4.711

2.  The Collective Effect of MIP-3α and FL Promotes Dendritic Cell Function Within the Immune Microenvironment of Murine Liver Cancer.

Authors:  Haichao Zhao; Changzhou Chen; Xidong Chen; Chuanli Yang; Donglin Zhang; Yanjun Li; Haoliang Zhao; Jiefeng He
Journal:  Front Oncol       Date:  2021-03-26       Impact factor: 6.244

3.  MicroRNA-5112 Targets IKKγ to Dampen the Inflammatory Response and Improve Clinical Symptoms in Both Bacterial Infection and DSS-Induced Colitis.

Authors:  Xilong Kang; Yang Jiao; Yingying Zhou; Chuang Meng; Xiaohui Zhou; Li Song; Xinan Jiao; Zhiming Pan
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.